Move
Toward Better Communication and Collaboration Among Patients, Payers, and
Product Developers
DIA and the Brookings Institution are
collaborating to strengthen communication between health care stakeholder
communities. A Model of Patient, Payer, and
Product Developer Collaboration to Support Innovating for Value
will focus on highlighting the perspectives and outcomes most relevant to
patient communities, reimbursement requirements and innovative payment
models of most interest for payer groups, and how both can help inform
product developers as they drive toward novel value-based innovation.
By exploring these issues and setting
an actionable agenda for improving communication moving forward, this
conference will be an important step toward ensuring that patients,
payers, and product developers are each contributing to the creation of
cost-effective, quality-producing therapies.
|
|
DIA Members Save $100. Register by
October 9!
|
Session Topics:
• Aligning Perspectives on Value and Outcomes
• Identifying Stakeholder Needs and Challenges
to Strategic Communication
• Exploring Opportunities for Efficient
Engagement Throughout Discovery,
Clinical Development, Regulatory
Review, and Product Use
• Case Studies and Current Initiatives
• Next Steps: Charting a Course Forward
• And More
Keynote Speaker:
• James
Heywood, Co-Founder, Chairman, PatientsLikeMe
Confirmed Speakers:
• Anne
C. Beal, MD, MPH, Chief Operating Officer,
Patient-Centered Outcomes Research Institute
• Marc
M. Boutin, JD, Executive Vice President and Chief
Operating Officer, National Health Council
• Shari
M. Ling, MD, Deputy Chief Medical Officer, Centers for
Medicare & Medicaid Services
Center for Clinical Standards &
Quality
• Sean
R. Tunis, MD, MSc, President and CEO, Center for Medical
Technology Policy
• Rhonda
M. Medows, MD, FAAFP, Executive Vice President &
Chief Medical Officer
UnitedHealthcare
• Tehseen
Salimi, MD, Vice President of Global Evidence and Value
Development, Sanofi Aventis
• Frances
M. Visco, President, National Breast Cancer Coalition
• Reed
V. Tuckson, MD, FACP, Managing Director, Tuckson Health
Connections, LLC
Who Should Attend?
• Patient groups interested in strengthening
patient involvement in medical product development
• Payer groups involved in reimbursement for
innovative new products
• Product developers considering the role of
external stakeholders in the creation of cost-effective,
quality producing medical products
• Regulators, providers, and academic
researchers pursuing cross-sector collaboration to
improve health care stakeholder
communication
Co-sponsored by:
More Exciting Offerings:
The annual conference where all
stakeholders in the rare disease/orphan product community convene to
focus on rare diseases and orphan product research, development, and
access. Search the Online Program.
Gain insight into the tradeoffs and
various stakeholder perspectives for developing a study endpoint
measurement strategy, including detailed and practical tips for ensuring
that measurement tools are adequate to support the targeted objectives
with a focus on establishing instrument content validity for the
specified clinical trial context of use.
Join FDA, EMA, Health Canada, and
other regulatory agencies, patient, industry and academic representatives
to discuss the progress and application of Benefit-risk assessment
throughout the development and post-approval life cycle.
|
